tbuckley/cabot-search huggingface dataset:
Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis
Authors: Paige W. Wolstencroft, Lorinda Chung, Shufeng Li, Livia Casciola-Rosen, David F. Fiorentino
Journal: JAMA Dermatology (2017)

Cutaneous disease represents a significant burden for patients with dermatomyositis. However, quantitative estimates of the probability of skin disease remission and clinical factors associated with skin outcomes are lacking.To characterize cutaneous disease course in adult patients with dermatomyositis.Prospective cohort study conducted at a dermatology clinic at a tertiary academic referral center. All adult patients with dermatomyositis (age >18 years) seen between May 15, 2007, and October 28, 2016, were eligible. Patients were included in the current analysis if they had a baseline Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score of 12 or higher, and 2 or more CDASI scores separated by 3 months or more within their first 3 years of follow-up.The percentage of patients who achieved clinical remission of their cutaneous disease as measured by the CDASI over a 3-year follow-up.A total of 74 patients met our inclusion criteria (mean [SD] age at initial CDASI scoring, 54 [13] years; 58 women [78%]), and 28 (38%) achieved clinical remission during our 3-year follow-up period. Increased age (odds ratio [OR], 1.07; 95% CI, 1.02-1.12; P = .01), a dermatomyositis-associated malignancy (OR, 14.46; 95% CI, 2.18-96.07; P = .01), and treatment with mycophenolate mofetil (OR, 6.00; 95% CI, 1.66-21.78; P = .01) were significantly associated with clinical remission of skin disease in multivariable analysis. Patients with anti-melanoma differentiation-associated protein 5 antibodies had a significantly lower probability of meeting outcome criteria in our time-to-event analysis. Baseline cutaneous disease activity, disease duration at baseline, and disease duration before first systemic therapy were not significantly associated with clinical remission of skin disease.Clinical remission was relatively uncommon in our population despite aggressive systemic therapy, and patients with anti-melanoma differentiation-associated protein 5 antibodies were even less likely to enter clinical remission during a 3-year follow-up period. Although mycophenolate mofetil compared favorably with other treatment options, our data provide evidence that a substantial population of patients with dermatomyositis have skin disease that is not adequately managed with standard-of-care therapies.
Results of a Phase 2 Trial Evaluating Efficacy and Safety of Entospletinib (GS-9973) in Patients with Mantle Cell Lymphoma
Authors: Jeffrey P. Sharman, Kathryn S. Kolibaba, Andrei R. Shustov, Thomas A. Giever, Leonard M. Klein, Derek Nay, Thomas A. Rado, Alfred Saleh, Danjie Zhang, Wen Shi, Andres Forero, Sarit Assouline
Journal: Blood (2016)
EXTH-72. CELECOXIB INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN GLIOMA STEM CELLS AND AN ANIMAL MODEL OF GLIOBLASTOMA
Authors: Kenji Shono, Akiko Sumi, Toshitaka Fujihara, Kohei Nakajima, Yoshifumi Mizobuchi, Keiko Kitazato, Shinji Nagahiro, Hideo Mure
Journal: Neuro-Oncology (2017)

Biological characteristics of glioblastoma multiforme (GBM), such as resistance to chemo- and radiotherapy and their infiltrative and proliferative nature, suggest that these tumors contain cancer stem cells. However, there are few reports of drug treatments for gliomas that specifically target stem cells. Cyclooxygenase (COX)-2 overexpression is associated with increased angiogenesis, tumor invasion, and the development of tumor cell resistance to apoptosis. Celecoxib is a selective COX-2 inhibitor that has shown anti-neoplastic activity in several malignancies, but this has not been investigated in glioma stem cells (GSCs). We addressed this in the present study by examining the effect of celecoxib on GSCs derived from neural stem cells. Celecoxib induced apoptosis and inhibited proliferation in GSCs. In an orthotopic animal model of GBM, celecoxib suppressed tumor growth, prolonged survival, and reduced the expression levels of C-C motif chemokine ligand 2 and C-X-C motif chemokine ligand 10, which are associated with monocyte infiltration and cell proliferation, respectively. These results provide evidence for the anti-neoplastic activity of celecoxib in GSCs and suggest that it can be effective for the treatment of GBM.
Abstract 17789: Externally Applied Vibroacoustic Stimulation (VATS) Enhances Thrombolytic Activity of Tissue Plasminogen Activator (t-PA) in an in-vitro Model of Acute Stroke
Authors: Arkady Uryash, Reza Jahan, Jose A Adams
Journal: Circulation (2017)

Background: Thrombotic ischemic stroke affects over 400,000 people in the United States annually and a third leading cause of mortality. Thrombolysis in occluded arteries may reduce brain injury if...
RTHP-05. EFFECTIVENESS OF PET-CT AS A GUIDE FOR PALLIATIVE RADIATION THERAPY FOR SPINAL METASTASES 
Authors: Crystal Adams, Gregory Davis, Anthony Caputy, Jonathan Sherman
Journal: Neuro-Oncology (2017)

Epidural spinal metastases occur in as many as 8% of cancer patients and typically present in multiple spinal levels. As back pain is the presenting symptom in 95% of these patients, appropriately identifying and treating the most symptomatic levels can provide significant palliation to this patient population. PET-CT is a traditional method for identifying the extent of systemic metastatic disease. The purpose of this study is to analyze the ability of PET-CT to identify spinal metastases with high metabolic activity and its utility in guiding radiotherapy. We sought to correlate improvement in back pain with reduction in SUV uptake following treatment. We conducted a retrospective review of 72 patients with bony spinal metastases treated with stereotactic ablative radiation therapy at Virginia Hospital center between 2004 and 2012. PET-CT was used to calculate SUV values for their spinal metastases and treatment planning was based on PET-CT results. Pre- and post-operative pain level was assessed in all patients. Analyses revealed a reduction in pain scores in 78% of treated patients. A significant reduction in pain was identified in patients with greater than 5 metastases as compared to a fewer number of lesions (p<0.05) Degree of change in SUV correlated with pain relief but did not reach statistical significance. In addition, maximum SUV did not play a role in pain reduction in this analysis. Within the limitations of our study, PET-CT was a useful adjunct in radiation treatment planning with change in SUV correlating with symptomatic improvement. This study paves the way for future prospective studies to further assess the utility and cost-effectiveness of this imaging modality in radiation treatment planning for spinal metastases.
P2.02-071 Prospective Molecular Study of 22 Genes by NGS in Patients with Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Single Institution Experience
Authors: V. Denninghoff, G. Recondo, M. Cuello, V. Romano, V. Wainsztein, F. Galanternik, M. Greco, M. De La Vega, M.A. Avagnina, G. Recondo
Journal: Journal of Thoracic Oncology (2017)
NIMG-89. DEEP LEARNING APPROACHES TO IDENTIFY INTRA-TUMORAL HETEROGENEITY OF LOW AND HIGH GRADE GLIOMAS
Authors: Peter Chang, Daniela A Bota, Christopher Filippi, Daniel Chow
Journal: Neuro-Oncology (2017)

Deep learning is an emerging branch of artificial intelligence rapidly outperforming conventional benchmarks on various computer vision tasks. The present study evaluates a novel deep learning architecture in automatically predicting IDH mutation from conventional MRI and identifying tumor sub-regions that are most characteristic of mutation status. MR imaging data from The Cancer Imaging Archives and corresponding genomic data were downloaded for patients with low (LGG) and high-grade gliomas (HGG). Only patients with full preoperative MR including T2, FLAIR, precontrast-T1 and postcontrast-T1 were analyzed. A novel 3D fully connected deep learning architecture was trained to predict the likelihood of IDH mutation at any given voxel. Final prediction for a given tumor was based on the mean prediction for the tumor volume. A total of 5,259 axial slices of tumor from 457 glioma patients (200 LGG, 257 HGG) were included for analysis. Overall the algorithm correctly predicted IDH mutation with 94% accuracy on five-fold cross-validation. The resulting heat map for voxel-wise prediction identifies tumor sub-regions containing features most characteristic of IDH mutation. Visually these features include faint or absent enhancement as well as central cystic regions with FLAIR suppression. A deep learning algorithm can predict IDH mutation with high accuracy from conventional MRI. In addition the algorithm is objective (requires no human interaction) and fast (several seconds from raw imaging data to prediction). Further investigation is ongoing to identify the best way to synthesize this data into clinical treatment paradigms.
NHS needs £4bn boost in budget to protect care, think tanks warn
Authors: Gareth Iacobucci
Journal: BMJ (2017)

The government must commit at least £4bn (€4.5bn; $5.3bn) more to the NHS in the autumn budget to prevent patient care from worsening next year, three leading healthcare think tanks have warned.

In a joint analysis issued ahead of the chancellor’s budget on 22 November the Health Foundation, the King’s Fund, and the Nuffield Trust estimated that the government’s current spending plans fall well short of what the NHS needs based on projections from the Office of Budget Responsibility and historic rates of funding growth.1 The think tanks estimated a funding gap of at least £20bn by 2022-23 based on current spending plans.

The briefing said …
OA 17.08 Phase II Study of Pembrolizumab for Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Following Completion of Locally Ablative Therapy (LAT)
Authors: J. Bauml, R. Mick, C. Ciunci, C. Aggarwal, T. Evans, L. Miller, N. Muhammad, E. Alley, C. Knepley, F. Mutale, R. Cohen, C. Langer
Journal: Journal of Thoracic Oncology (2017)
HOUT-26. SURVIVAL PATTERNS, OUTCOMES, AND QUALITY OF LIFE IN A CLINICAL SERIES OF PRIMARY GLIOBLASTOMA
Authors: Anna Lintelmann, Meghan Hultman, Anna Babcock, John Trusheim, Patricia Bruns, Nilanjana Banerji
Journal: Neuro-Oncology (2017)

Despite advances made in treatment of glioblastoma, prognosis still remains poor, with a reported median survival of 14.6 months. We report here the treatment patterns, survival, and quality of life in patients with glioblastoma in a real-world setting. From October 2015 to April 2017, 31 consecutive patients with primary glioblastoma treated at Abbott Northwestern Hospital were enrolled in this study. Demographic, pathologic, and clinical information was abstracted from electronic medical records. Quality of life (QOL) was measured at baseline and specified time-points during treatment with the MD Anderson Symptom Inventory - Brain Tumor questionnaire. The median age of patients was 57 years (range, 23-78); a total of 74.2% of the patients were male, and 25.8% were aged >65 years. Twenty-nine patients had a gross total resection of their tumor and 27 patients received 6 weeks of radiation and chemotherapy post-surgery. Patients received adjuvant temozolomide for a median of 6 cycles (range, 2-10). MGMT methylation was observed in 9 cases and none of the patients had IDH mutations. Second-line therapy consisted of bevacizumab monotherapy in 61.1% patients. One patient participated in a clinical trial prior to progression, and 1 patient participated in a clinical trial after progression. Optune treatment was administered in 11 patients before tumor progression. Median progression-free survival noted in this series was 9 (7-10) months. Median overall survival for the participants did not drop below 50 % during the study duration. Three or more moderate to severe treatment related symptoms were observed in 42.7% patients. Survival results identified in this real-world setting study were comparable to the survival rates noted in controlled clinical trials. Our data indicate that exceptional survival rates in the general population with glioblastoma may be achieved with a multidisciplinary treatment approach, with acceptable QOL during the process.
CMET-10. EFFECT OF EGFR AND ALK MUTATIONS ON THE OUTCOME OF STAGE III LUNG CARCINOMA PATIENTS WITH BRAIN METASTASIS - CLEVELAND CLINIC EXPERIENCE
Authors: Jyothirmai Seepana
Journal: Neuro-Oncology (2017)

Lung Cancer is the leading cause of mortality in men and women diagnosed with cancer world-wide. Among patients diagnosed with lung cancer, non-small cell lung cancer (NSCLC) is one of the most common type consisting predominantly Adenocarcinoma, Squamous cell carcinoma, and large cell carcinoma. Patients with stage III NSCLC are referred to multi-modality treatment protocols which includes chemo-therapy, radio-therapy or both and surgery when feasible. Molecular technology has enabled identification of mutations like EGFR (Epidermal growth factor receptor) and ALK (Anasplatic lymphoma kinase). With the advances in targeted therapy, the aim of the study is to compare the PFS and OS in the patients with positive mutations having brain metastasis to those who had negative mutation. In a retrospective study, the Cleveland Clinic’s database was used to identify stage III NSCLC patients treated through 2003–2014. There were a total of 734 patients in the study. NSCLC Stage III was characterized by clinical or pathological stage. Kaplan-Meier estimate was used to determine the survival of patients by conducting a regression of OS and PFS against time since treatment was begun. 2-year survival and 5-year survival were treated as binary variables. There were a total of 734 patients in the study. Overall 130 patients had brain metastasis out of 734 patients i.e. approximately 18%. 202 patients had a mutation status which was observed to be either positive or negative. 23 patients with mutation negative status had brain metastasis, 2 patients with EGFR positive and 1 patient with ALK positive mutation had brain metastasis. Hazard Ratio (HR) (95% CI); Overall Survival 0.36 (0.047, 2.80) p = 0.33; PFS 0.27 (0.035, 2.13) p = 0.21. In stage 3 lung carcinoma patients, no statistically significant difference was observed in the OS and PFS for patients with brain metastasis having positive mutation status.
P2.05-050 Impact of Inflammation and Sarcopenia on Outcomes after Stereotactic Body Radiotherapy for T1N0M0 Non-Small Cell Lung Cancer
Authors: Yukinori Matsuo, Yasushi Nagata, Masashi Wakabayashi, Junko Eba, Satoshi Ishikura, Hiroshi Onishi, Masaki Kokubo, Katsuyuki Karasawa, Yoshiyuki Shioyama, Rikiya Onimaru, Masahiro Hiraoka
Journal: Journal of Thoracic Oncology (2017)
P3.02-086 MGA Suppresses the MYC Pathway in Lung Adenocarcinoma
Authors: P. Llabata, Y. Mitsuishi, P. Choi, M. Torres-Diz, D. Cai, X. Zhang, M. Sanchez-Cespedes, M. Meyerson
Journal: Journal of Thoracic Oncology (2017)
PATH-51. OUTCOME IN 1p/19q NON-CO-DELETED GLIOMA TREATED AT FIRST RECURRENCE WITH TEMOZOLOMIDE W/WO BEVACIZUMAB IS DEPENDENT ON IDH, MGMT AND CIMP STATUS, BUT NOT ON GRADE AT FIRST DIAGNOSIS. A REPORT FROM THE RANDOMIZED PHASE II EORTC TAVAREC TRIAL
Authors: Pim French, Iris de Heer, Kaspar Draaisma, Johan Kros, W Taal, Jacolien Bromberg, Paul Clement, Ahmed Idbaih, Filip de Vos, Antje Wick, Paul Mulholland, Martin Taphoorn, Joanne Lewis, Tina Verschuere, Vassilis Golfinopoulos, Thierry Gorlia, Martin van den Bent
Journal: Neuro-Oncology (2017)

The TAVAREC randomized controlled phase II trial examined the efficacy of bevacizumab in addition to temozolomide in non-1p19q co-deleted grade II/IIII glioma treated at first recurrence showing contrast enhancement. The trial failed to demonstrate improvement of PFS or OS when bevacizumab was added to temozolomide. Here we present data on the molecular analysis of trial samples. Tumors were reviewed for areas with high tumor percentage. IDH1 and IDH2 mutation status was determined via Sanger sequencing and using immunohistochemistry (n=127/155). Methylation analysis was done using the InfiniumMethylationEpic beadchip (Illumina, n=122/155) from which G-CIMP, 1p/19q and MGMT promoter methylation status (MGMT-STP27) were determined. Trial arms were combined in the prognostic factor analysis. All statistical analyses were performed at 5% significance. Mutations in IDH1 were found in 97/127 samples and was associated with favorable prognosis. No mutations in IDH2 were identified. 1p/19q codeletion was identified in three tumors. MGMT promoter methylation was present in 89/122 samples (n=33 unmethylated) and was associated with more favorable outcome. Ninety-two tumors were assigned to the prognostically favorable G-CIMP positive subtype (n=30 G-CIMP negative). IDH-mutation status, G-CIMP status and MGMT promoter methylation status were all correlated (P<0.0001). Tumor grade at initial diagnosis was no longer prognostic at tumor recurrence for OS and PFS (also when analysing IDH-mutant tumors only). Multivariate analysis including the molecular and clinical data shows that lesion size, steroids, G-CIMP status and MGMT promoter methylation status are associated with outcome. None of the molecular markers were associated with improved outcome to bevacizumab. In temozolomide-treated recurrent grade II/III non-1p/19q co-deleted tumors, IDH status is prognostic but multivariable analysis indicates CIMP and MGMT status are of more significance. As tumor grade at diagnosis is no longer prognostic in recurrent IDH-mutated, 1p/19q intact tumors, they can be studied together in future clinical trials.
P3.01-054 Urinary ct-DNA Testing of EGFR Common Mutation in Non-Small Cell Lung Cancer Patients
Authors: A. Ridwanuloh, H. Hariyatun, F. Patria, A. Hudoyo, J. Zaini, S. Andarini, N. Masykura, A. Utomo
Journal: Journal of Thoracic Oncology (2017)
The prognostic impact of sidedness across all stages during the last 20 years: the “Modena Cancer Registry” experience
Authors: A. Spallanzani, F. Gelsomino, F. Caputo, M. Salati, L. Reggiani Bonetti, F. Domati, K. Andrikou, A. Fontana, K. Di Emidio, C. Baldessari, G. Pugliese, S. Bettelli, G. Luppi, S. Cascinu
Journal: Annals of Oncology (2017)
Une épidémie de kératoconjonctivite à adénovirus 8 dans une maison de retraite à Madrid
Authors: J M Sendra Gutierrez, D Martin Rios, I Casas, P Sáez, A Tovar, C Moreno
Journal: Eurosurveillance (2004)

Cet article decrit et analyse une epidemie de keratoconjonctivite survenue dans une maison de retraite a Leganes (une ville pres de Madrid) en 2001-2002. C'est la premiere fois qu'une epidemie presentant ces caracteristiques et avec une identification du serotype est publiee en Espagne. 
Les caracteristiques socio-demographiques, la courbe epidemique et les taux d'attaque sont decrits. La comparaison des donnees a ete realisee par le test chi2 et par le test T pour les donnees qualitatives et quantitatives. Les facteurs associes a la maladie ont ete etudies a l'aide de tables de contingence et de modeles de regression logistique. 
Cent deux cas ont ete detectes avec un taux d'attaque de 36,4% chez les residents et 12,9% chez les employes, sans tenir compte des differences spatiales ou professionnelles. La courbe epidemique montre un schema de transmission de personne a personne. L'analyse multivariee a permis d'identifier les facteurs de risque suivants chez les residents : capacite a se deplacer de facon autonome dans les locaux, incontinence urinaire et partage d'une salle de bains. Un adenovirus de serotype 8 de meme sequence genomique a ete detecte dans 34,6% des prelevements de conjonctivite. 
Les facteurs cles pour prevenir et controler ces epidemies en milieu clos sont la mise en place de normes hygieniques adaptees au nettoyage de ce type de locaux et aux soins aux malades, ainsi qu'un diagnostic precoce et une bonne coordination des ressources tant humaines que materielles.
PDCT-13. ASSESSMENT OF NEUROCOGNITION AND BRAIN CONNECTIVITY IN PEDIATRIC BRAIN TUMOR PATIENTS
Authors: Stephanie Perkins, Joshua Rubin, Bradley Schlaggar, Joshua Shimony, Dennis Barbour, David Limbrick, Nico Dosenbach
Journal: Neuro-Oncology (2017)

While most pediatric brain tumor patients become long-term survivors, there are known long-term effects in processing speed, executive function and other cognitive domains secondary to surgery, radiation therapy, chemotherapy, and the tumor itself. However, the effects of these factors on the functional neuroanatomy underlying cognition is poorly understood.
SCDT-47. NATIONAL PATTERNS AND OUTCOMES OF INITIAL INTERSTITIAL BRACHYTHERAPY FOR CNS NEOPLASMS
Authors: Bryan Iorgulescu, Saksham Gupta, Cheryl Zogg, Tim Smith
Journal: Neuro-Oncology (2017)

Despite increasing therapeutic promise and advances, the national patterns of interstitial brachytherapy remain unknown. The US National Cancer Database, comprising ~70% of all newly-diagnosed cancers, was analyzed for brachytherapy-treated CNS neoplasms (2004-2014). 325 patients with newly-diagnosed primary CNS neoplasms underwent brachytherapy (i.e. interstitial, intracavitary, or intravascular radiotherapy) as part of their initial treatment. 77 (24%) were exclusively encoded as interstitial (results reported below), compared to 21% as intracavitary, 27% as I131/P32 radioisotopes, and 29% brachytherapy NOS. Median age at diagnosis was 61yo (IQR:50-72), with 51% male patients. 54% were treated at comprehensive cancer programs and 30% at academic programs; predominantly in New England (37%). Insurance was commonly private (55%) and Medicare (35%). The predominant tumor types were glioma (77%, 53/59 were GBM) and meningioma (12%). Patients underwent interstitial brachytherapy a median of 14d after diagnosis (IQR: 4-35). 61% of cases employed a high-rate radioisotope source. Patients additionally underwent chemotherapy (50%) and beam radiotherapy (30%), as indicated. Only 77% of patients were encoded as having surgery, 45% in which the definitive surgery included intraoperative interstitial radiotherapy-only 1 of which experienced a (unplanned) readmission within 30d, and 98% were alive at 30d. Despite the increasing interest in interstitial therapies, national registry standards have not been updated to appropriately capture these treatments. The NAACCR (sponsored by NCI/CDC/AJCC/ACS), which sets state/national cancer registration standards and forms the basis for national datasets like SEER and NCDB, presently doesn’t incorporate information on chemo/immunotherapy or I131/P32 delivery modality, only encodes surgical EOR, and lacks brachytherapy radiodosage/parameters. Nevertheless, our limited national sample supports the 30d safety of interstitial brachytherapy in the initial treatment of CNS neoplasms. It’s crucial for the interstitial therapeutics community to continue working with registry and billing standards agencies to ensure the appropriate integration of these exciting modalities into common practice.
Eosinophilic esophagitis (EoE) genetic susceptibility is mediated by synergistic interactions between EoE-specific and general atopic disease loci
Authors: Lisa J. Martin, Hua He, Margaret H. Collins, J.Pablo Abonia, Joceyln M. Biagini Myers, Michael Eby, Hanna Johansson, Leah C. Kottyan, Gurjit K. Khurana Hershey, Marc E. Rothenberg
Journal: Journal of Allergy and Clinical Immunology (2017)
EWGLI: Programa Europeo de Vigilancia de la Legionelosis Asociada a Viajes
Authors: E. J. Hutchinson, C Joseph, C L R Bartlett
Journal: Eurosurveillance (1996)

El Grupo Europeo de Trabajo sobre Infecciones por Legionella (EWGLI) se creo en 1986 y, en 1987, presento el Programa Europeo de Vigilancia de la Legionelosis Asociada a Viajes. Los microbiologos que trabajan en laboratorios de referencia y los epidemiologos que participan en programas nacionales de vigilancia de la legionelosis en los paises miembros, reconocen que los brotes de legionelosis pueden ser identificados precozmente gracias al intercambio de informacion. De acuerdo con ello, los objetivos del programa son la identificacion de agrupaciones de casos de legionelosis que puedan indicar la existencia de una fuente comun, alertar rapidamente a los centros colaboradores, y el mantenimiento y desarrollo de una base de datos de vigilancia europea.